Trials / Recruiting
RecruitingNCT07229027
Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Medialis Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
Detailed description
Despite evidence on the burden of BMI \>25, few disease-specific instruments comprehensively capture its multidimensional impact. Existing frameworks often target obesity (BMI ≥30) or patients on pharmacological or surgical therapy. Overweight and extremely obese populations are underrepresented, and economic and psychosocial dimensions are rarely integrated into severity staging. This study, therefore, aims to systematically evaluate symptoms, comorbidities, HRQoL, and costs across the full spectrum of individuals with BMI \>25, excluding those on GLP-1 therapy. Integrating clinician and patient perspectives will support the development of more inclusive severity measures and inform early intervention strategies.
Conditions
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2026-07-01
- Completion
- 2026-08-01
- First posted
- 2025-11-14
- Last updated
- 2025-11-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT07229027. Inclusion in this directory is not an endorsement.